Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of the basic neurological condition associated with sialorrhea (as above, (i), (ii) or (iii); with onset at least 6 months before screening).~* Chronic troublesome sialorrhea related to parkinsonism or stroke or traumatic brain injury (for at least 3 months) at screening, defined as the presence of all of the following, at screening and at baseline and for at least the 3 months before screening (where retrospective response to questionnaires is impossible, a statement of equivalent severity will suffice):~  1. A Drooling Severity and Frequency Scale \[DSFS\] sum score of at least 6 points and~ 2. A score of at least 2 points for each item of the DSFS and~ 3. A score of at least 3 points on the modified Radboud Oral Motor Inventory for Parkinson's Disease \[mROMP\], Section 'III Drooling', Item A).~* A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and a score of at most 3 points on Item C), at screening and at baseline.~Exclusion Criteria:~* Non-neurological secondary causes of sialorrhea.~* Unstable concomitant medication influencing sialorrhea (such as anticholinergics for the treatment of parkinsonism; dosages of these medications must have been stable for at least 4 weeks before study entry, i.e. screening, and must be planned to remain stable during the course of the study.~* Recent (i.e., four weeks) drug treatment for sialorrhea.~* History of recurrent aspiration pneumonia.~* Extremely poor dental/oral condition as assessed by a qualified dentist.~* Recent (i.e., one year for sialorrhea, 14 weeks for other indications) treatment with - or known hypersensitivity to - Botulinum toxin, or known hypersensitivity to any ingredient of the study preparation.~* Recent (i.e., four weeks) changes in anti-parkinsonian medication.~* Previous or planned surgery or irradiation to control sialorrhea.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IncobotulinumtoxinA (Xeomin) (100 Units) (Type: EXPERIMENTAL): * Main period (1 treatment cycle): Subjects to receive 100 Units.~* Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)
- IncobotulinumtoxinA (Xeomin) (75 Units) (Type: EXPERIMENTAL): * Main period (1 treatment cycle): Subjects to receive 75 Units.~* Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)
- Placebo (Type: PLACEBO_COMPARATOR): * Main period (1 treatment cycle): Subjects to receive placebo injection.~* Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~* Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)

Based on this trial design, predict the completion outcome and termination type (if applicable).